Novartis’ groundbreaking cancer T-cell therapy CTL019 has won unanimous backing from advisers to the FDA, paving the way for approval in the coming months. There had been concerns that the ...

“New technologies such as gene and cell therapies hold out the potential ... coming just two days after Gilead announced it is buying Novartis’ close CAR-T rival, Kite Pharma for $12 billion.

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

A cancer therapy that uses genetically engineered immune cells, called CAR T-cells, has kept a person free of a potentially fatal nerve tumour for a record-breaking 18 years. “This is ...

After injection, the CAR-T cells got to work, multiplying and seeking out the target B cells, including the pathogenic ones underlying the autoimmune conditions. This persisted for a few weeks ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

CAR T-cell expansion and persistence were superior ... Kotecha disclosed relationships with Eisai, Allogene Therapeutics, Exelixis, Novartis, Pfizer, Takeda, and Xencor. Campbell and Tannir ...

To create one of the most advanced immunotherapies in cancer, CAR-T cell therapies, scientists engineer immune T cells to carry a synthetic protein on their surfaces. This protein, called the ...

Global CAR T Cell Therapy Market is estimated to valued at US$ 2.26 Bn in 2022 and expected to exhibit a CAGR of 20.9 % during the forecast period (2022-2030). BURLINGAME, CA, UNITED STATES ...

Despite the powerful cancer-fighting capabilities of treatments based on T cells containing an engineered chimeric antigen receptor (CAR) to fight a patient’s cancer, one key challenge is ...